

THE JOHNS HOPKINS HOSPITAL TO PRESENT STUDY DATA ON APAS® INDEPENDENCE

Independent evaluation data to be presented at the ASM Microbe Conference held in Chicago, June 2020

Adelaide, Australia, 12 March 2020: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce that The Johns Hopkins Hospital, has been accepted to present clinical study data, comprising their independent evaluation of the APAS® Independence at the ASM Microbe Conference in Chicago in June 2020.

The Johns Hopkins Hospital in Baltimore, Maryland, United States has conducted an independent assessment of the APAS® Independence, evaluating its ability to successfully screen chromogenic culture plates for the presence of Methicillin-resistant *Staphylococcus aureus* or MRSA. The study, using the APAS® MRSA analysis module, compared the results from the instrument with manual plate reading by a trained microbiologist. The results considered both the accuracy of the APAS® Independence to identify MRSA as well as its ability to deliver efficiencies within a routine clinical setting. Details of the outcome of the evaluation will be presented at the American Society of Microbiology annual conference ASM Microbe in Chicago in June 2020. The presentation will be released to the ASX when presented and is titled:

Comparison of an Automated Plate Assessment System and Artificial Intelligence (AI) to Manual Plate Reading of Methicillin-Resistant *Staphylococcus aureus* Chromagar Surveillance Cultures

As a world-renowned reference site, The Johns Hopkins Hospital seek to gain access to the latest technologies available and have broad experience conducting clinical evaluations of new technologies. This study will provide an independent, highly renowned reference point and data set for potential customers to learn what efficiencies the APAS® Independence can deliver for their laboratory. As an independent technology evaluation, there is no commitment from The Johns Hopkins Hospital in relation to purchasing the instrument. The microbiology department of the Johns Hopkins Hospital is also a highly specialised test facility rather than a bulk pathology testing centre.

LBT CEO and Managing Director, Brent Barnes said:

"Independent evaluations supported by data are a key reference point for our customers and we are excited to be able to demonstrate the positive performance of the APAS® Independence at a prestigious institution such as The Johns Hopkins Hospital. I'd like to thank the team at The Johns Hopkins Hospital for their time and effort taken to conduct the evaluation. We also look forward to being able to share their outcomes with the broader clinical community and our potential customer base once they are published, as we continue to build our reference sites."

About ASM Microbe

The American Society of Microbiology, ASM Microbe conference is the leading microbiology conference held in the United States, bringing together key laboratory decision makers from around the country. As with previous years, LBT's 50% joint venture company, Clever Culture Systems will be exhibiting the APAS® Independence at its booth during the conference. The conference will be held in Chicago from 18-22 June.

Approved for release by the Chair of the LBT Board

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: jgranger@hawkesburypartners.com